Information Provided By: 
Fly News Breaks for October 7, 2016
MACK
Oct 7, 2016 | 06:14 EDT
JPMorgan analyst Anupam Rama downgraded Merrimack Pharmaceuticals to Neutral saying the shares are likely to be range-bound after rallying 36% from the 52-week low on September 20. Key pipeline catalysts aren't likely until Q2 of 2017 and beyond while 2016 estimates are not "meaningfully beatable," Rama tells investors in a research note. He lowered his price target for the shares to $7 from $8.
News For MACK From the Last 2 Days
There are no results for your query MACK
